-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GEE1Sl8QCSM685UqkVIB1lWBNUE1LJD5rJLg9z79PkYdZMB1c2MpfO81sY2cv8vn
 cpHoa9ZAKwJxS9205c7jug==

<SEC-DOCUMENT>0001047469-03-031879.txt : 20030926
<SEC-HEADER>0001047469-03-031879.hdr.sgml : 20030926
<ACCEPTANCE-DATETIME>20030926171345
ACCESSION NUMBER:		0001047469-03-031879
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20030926
ITEM INFORMATION:		Financial statements and exhibits
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20030926

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRISTOL MYERS SQUIBB CO
		CENTRAL INDEX KEY:			0000014272
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				220790350
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01136
		FILM NUMBER:		03913133

	BUSINESS ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154
		BUSINESS PHONE:		2125464000

	MAIL ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRISTOL MYERS CO
		DATE OF NAME CHANGE:	19891012
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a2119463z8-k.txt
<DESCRIPTION>8-K
<TEXT>
<Page>

================================================================================


                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549



                                    FORM 8-K

                                 CURRENT REPORT

                       PURSUANT TO SECTION 13 OR 15 (d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


                       Date of report: September 26, 2003
               Date of earliest event reported: September 24, 2003


                          BRISTOL-MYERS SQUIBB COMPANY
             (Exact name of registrant as specified in its charter)


         Delaware                    1-1136                     22-079-0350
(State or other jurisdiction    (Commission file              (IRS Employer
     of incorporation)              number)               Identification Number)


                                 345 Park Avenue
                               New York, NY 10154
                     (Address of principal executive office)

       Registrant's telephone number, including area code: (212) 546-4000

================================================================================

<Page>

Item 7 (c).  Exhibits

Exhibit 99 - Press release of Bristol-Myers Squibb Company dated September 24,
2003 announcing the intention to offer convertible senior debentures.


Item 9. Regulation FD Disclosure

On September 24, 2003, Bristol-Myers Squibb Company issued a press release
announcing the intention to offer $1 billion of convertible senior debentures. A
copy of the press release is furnished as Exhibit 99 to this report and is
incorporated herein by reference.



                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.


                                      Bristol-Myers Squibb Company,


                                      By:  /s/ Sandra Leung
                                           -------------------------------------
                                           Name: Sandra Leung
                                           Title: Secretary

Date:  September 26, 2003



                                  EXHIBIT INDEX


EXHIBIT NO.     DESCRIPTION
- -----------     -----------

    99          Press Release dated September 24, 2003 of Bristol-Myers
                Squibb Company








</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>a2119463zex-99.txt
<DESCRIPTION>EXHIBIT 99
<TEXT>
<Page>
                                                                      Exhibit 99


FOR IMMEDIATE RELEASE


CONTACT:   Bonnie Jacobs                       John Elicker
           Corporate Affairs                   Investor Relations
           609-252-4089                        212-546-3775
           bonnie.jacobs@bms.com               john.elicker@bms.com


BRISTOL-MYERS SQUIBB ANNOUNCES OFFERING OF CONVERTIBLE SENIOR DEBENTURES

         NEW YORK, NEW YORK (September 24, 2003) -- Bristol-Myers Squibb (NYSE:
BMY) announced today that it intends to offer $1 billion of convertible senior
debentures through an offering to qualified institutional buyers pursuant to
Rule 144A under the Securities Act of 1933.

         The debentures are expected to have a term of 20 years (with a right by
the company to call them after five years, and a right by holders to put their
debenture every five years) and will be convertible into Bristol-Myers Squibb
common stock, at a price to be determined by negotiations between Bristol-Myers
Squibb and the initial purchasers of the debentures. The terms of the offering
are expected to include an option exercisable by the initial purchasers to
purchase up to an additional $200 million aggregate principal amount of
debentures.

         This press release does not constitute an offer to sell or the
solicitation of an offer to buy securities. The offering is being made only to
qualified institutional buyers. The convertible senior debentures being offered
have not been registered under the United States federal or state securities
laws and may

<Page>

not be offered or sold absent registration or an applicable exemption from the
registration requirements.

         Bristol-Myers Squibb is a global pharmaceutical and related health care
products company whose mission is to extend and enhance human life.

This press release contains "forward-looking statements" as that term is defined
in the Private Securities Litigation Reform Act of 1995. These statements are
based on management's current expectations and involve significant risks and
uncertainties. We undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.



                                       ###

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
